Unichem Laboratories Limited (BOM:506690)
357.50
-4.15 (-1.15%)
At close: May 26, 2026
Unichem Laboratories Revenue
In the fiscal year ending March 31, 2026, Unichem Laboratories had annual revenue of 22.65B INR with 7.29% growth. Unichem Laboratories had revenue of 5.99B in the quarter ending March 31, 2026, with 1.94% growth.
Revenue
22.65B
Revenue Growth
+7.29%
P/S Ratio
1.10
Revenue / Employee
7.21M
Employees
3,142
Market Cap
24.89B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.65B | 1.54B | 7.29% |
| Mar 31, 2025 | 21.11B | 3.26B | 18.25% |
| Mar 31, 2024 | 17.85B | 4.42B | 32.92% |
| Mar 31, 2023 | 13.43B | 731.90M | 5.76% |
| Mar 31, 2022 | 12.70B | 346.97M | 2.81% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Morepen Laboratories | 18.27B |
| Hikal | 17.25B |
| Gufic Biosciences | 8.97B |
| Bliss GVS Pharma | 8.68B |
| Venus Remedies | 7.82B |
| Lincoln Pharmaceuticals | 6.52B |
| Fredun Pharmaceuticals | 6.39B |
| Syncom Formulations (India) | 5.21B |
Unichem Laboratories News
- 2 days ago - Unichem Laboratories shares fall over 3% after weak Q4 results; Profit drops 79% YoY - Business Upturn
- 5 days ago - Unichem Laboratories Q4 Results: Net profit falls 79% YoY to Rs 10.9 crore, revenue declines 2% - Business Upturn
- 8 months ago - Unichem Laboratories shares fall 3% after €19.49 million EU penalty demand in perindopril case - Business Upturn
- 9 months ago - Unichem Pharmaceuticals recalls mislabeled Cyclobenzaprine tablets in US over safety concerns - Business Upturn
- 9 months ago - Unichem Laboratories’ Roha API facility gets VAI classification from USFDA - Business Upturn
- 1 year ago - Unichem Laboratories shares drop 4% after USFDA flags 3 procedural issues at Roha facility - Business Upturn
- 1 year ago - Unichem Labs Q4 Results: Revenue up 27.9% YoY to Rs 587.18 crore, company swings back to net profit - Business Upturn
- 1 year ago - Unichem Laboratories receives USFDA EIR for Pithampur facility; inspection classified as VAI - Business Upturn